Will Robots Choose What Drugs We Take in the Future? Psychiatrist Dr Raj Persaud talks to a pioneer of AI drug discovery
Description
You can also listen to this interview on a free app on iTunes and Google Play Store entitled 'Raj Persaud in conversation', which includes a lot of free information on the latest research findings in psychology, psychiatry, neuroscience and mental health, plus interviews with top experts from around the world. Download it free from these links. Don't forget to check out the bonus content button on the app.
https://play.google.com/store/apps/details?id=com.rajpersaud.android.rajpersaud
Peter Richardson
Peter Richardson serves as VP Pharmacology at BenevolentAI. He was a founding member of Cambridge Biotechnology Ltd in 2001 and served as CSO and Executive Director until 2005. Peter pioneered the sale of CBT to Proximagen Ltd, to whom he acted as an adviser until 2012. Between 1989 and 2006 he served as a Lecturer and Senior Lecturer in the Department of Pharmacology, University of Cambridge where he pioneered research into drug discovery for Parkinson’s disease and inflammation, as well as new gene expression technologies. He is the author of over 70 peer-reviewed scientific papers. Peter studied Biochemistry at the University of Oxford, and was awarded a doctorate in Biochemistry from the University of Cambridge.
United States
